SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences, Lupin sign licensing agreement to co-market Semaglutide Injection in India

17 Mar 2026 Evaluate

Zydus Lifesciences has entered into a Licensing and Supply Agreement with global pharma major, Lupin to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India. This partnership brings together the company’s strong product development capabilities and Lupin’s extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market the company’s innovative Semaglutide Injection in the Indian market under the brand names Semanext and Lupin’s Livarise. The company will market the product under the brand names SEMAGLYN, MASHEMA and ALTERME. Lupin will pay the company upfront licensing fees and milestone payments on achieving pre-defined milestones.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

891.65 -18.75 (-2.06%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×